India Pharma Outlook Team | Wednesday, 08 October 2025
ENTOD Pharmaceuticals announced the release of OCUBIOME, the first ocular probiotic blend in India formulated for healthy eyes.
It said its proprietary formulation was developed by its research center in Navi Mumbai. ENTOD Pharmaceuticals mentioned that dry eye syndrome and discomfort in the eyes have reached epidemic levels across different age groups because of increased screen time and changing patterns of corrective ocular surgeries.
The company noted that all day long millions deal with burning eyes, blurred vision, and post-surgical recovery. While therapies like lubricants have short-term efficacy, OCUBIOME is meant to work synergistically with them to restore balance to the ocular and gut microbiota and provide long-lasting effects on comfort and recovery.
Also Read: Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care
Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, said, “Eye health today cannot be addressed in isolation – it is impacted by lifestyle, environment, and recovery needs after surgery. With OCUBIOME, ENTOD is introducing a category-first innovation that brings freshness and convenience to how we manage ocular wellness.”
Dr Hitesh Chheda, Medical Director at Asian Eye Institute & Laser Centre, said, “Ocular health must be considered within the broader systemic context. Evidence shows that the gut microbiome plays a direct role in ocular inflammation and disease progression. ENTOD’s probiotic innovation provides clinicians with a scientifically supported option to improve outcomes in conditions such as dry eye and post-surgical recovery.”
The company stated the product will be available in mouth-melting, no-sugar-sachets, to be taken once a day for support of ocular comfort, recovery from digital eye strain, and long-term eye health. ENTOD Pharmaceuticals said the launch is a critical moment for preventive eye care. With ever-increasing awareness of the gut-eye axis, OCUBIOME provides an affordable approach to improving eye health rather than just masking symptoms. The company also said OCUBIOME will be available in November 2023.
